GSK (NYSE: GSK) execs add notional ADS through dividend reinvestment plan

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

GSK plc reported automatic acquisitions of notional American Depositary Shares by three senior figures through its Executive Supplemental Savings Plan. Dr Hal Barron, a non-executive director, acquired 2,300.572 notional ADS at $49.6700 per ADS following dividend reinvestment. On the same terms and date, James Ford, SVP and Group General Counsel, acquired 54.387 notional ADS and Maya Martinez-Davis, President, acquired 82.387 notional ADS. All transactions took place on 2026-05-15 on the New York Stock Exchange.

Key Figures

Dr Hal Barron notional ADS acquired: 2,300.572 ADS James Ford notional ADS acquired: 54.387 ADS Maya Martinez-Davis notional ADS acquired: 82.387 ADS +2 more

5 metrics

Dr Hal Barron notional ADS acquired 2,300.572 ADS Dividend reinvestment on 2026-05-15 at $49.6700 per ADS

James Ford notional ADS acquired 54.387 ADS Dividend reinvestment on 2026-05-15 at $49.6700 per ADS

Maya Martinez-Davis notional ADS acquired 82.387 ADS Dividend reinvestment on 2026-05-15 at $49.6700 per ADS

ADS acquisition price $49.6700 per ADS Price for all reported notional ADS acquisitions

Transaction date 2026-05-15 Date of all three notional ADS acquisitions

Key Terms

American Depositary Shares, notional ADS, Executive Supplemental Savings Plan, PDMR, +1 more

5 terms

American Depositary Shares financial

"Description of the financial instrument | American Depositary Shares ('ADS') ISIN: US37733W2044"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

notional ADS financial

"Acquisition of notional ADS within Dr Barron's GSK Executive Supplemental Savings Plan account"

Executive Supplemental Savings Plan financial

"within Dr Barron's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends"

PDMR regulatory

"Details of PDMR/person closely associated with them ('PCA')"

A PDMR (person discharging managerial responsibilities) is an individual who can shape a company’s strategy or finances—typically senior executives, board members, or close advisors with decision-making authority. Investors care because PDMRs often hold material, non‑public information and their buying or selling of shares must be reported; monitoring those disclosures is like watching a ship’s captain to read the likely course and spot possible insider risk.

LEI regulatory

"Name | GSK plc b) | LEI | 5493000HZTVUYLO1D793"

A Legal Entity Identifier (LEI) is a unique 20-character code assigned to a company or organization that participates in financial markets, like a corporate passport number. It helps investors and regulators unambiguously identify counterparties across databases and transactions, reducing confusion much like using a vehicle identification number to track a car’s history; clearer identification improves transparency, risk monitoring, and regulatory reporting.

Form 6-K: How Foreign Companies Report to the SEC →

05/19/2026 - 11:01 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of notional ADS within Dr Barron's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$49.6700	2,300.572

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-05-15
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of notional ADS within Mr Ford's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$49.6700	54.387

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-05-15
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Maya Martinez-Davis
b)	Position/status	President, US
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of notional ADS within Ms Martinez-Davis's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$49.6700	82.387

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-05-15
f)	Place of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)

Date: May 19, 2026

	By:/s/ VICTORIA WHYTE --------------------------

	Victoria Whyte
	Authorised Signatory for and on
	behalf of GSK plc

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did GSK (GSK) report in this Form 6-K?

GSK reported automatic acquisitions of notional American Depositary Shares by three senior individuals through its Executive Supplemental Savings Plan, all resulting from dividend reinvestment on 15 May 2026 on the New York Stock Exchange at a price of $49.6700 per ADS.

Which GSK (GSK) executives acquired notional ADS and in what amounts?

Dr Hal Barron acquired 2,300.572 notional ADS, James Ford acquired 54.387 notional ADS, and Maya Martinez-Davis acquired 82.387 notional ADS. All these acquisitions occurred within GSK’s Executive Supplemental Savings Plan via dividend reinvestment at a price of $49.6700 per ADS.

How were the GSK (GSK) notional ADS acquired by insiders structured?

The notional ADS were acquired within each individual’s GSK Executive Supplemental Savings Plan account. The filing states these acquisitions followed the reinvestment of dividends, meaning cash dividends credited under the plan were used to acquire additional notional ADS at a specified price.

On what date did the GSK (GSK) insider notional ADS acquisitions occur?

All three insider transactions occurred on 2026-05-15. The filing specifies that the acquisitions of notional American Depositary Shares through dividend reinvestment in the Executive Supplemental Savings Plan were executed on that date on the New York Stock Exchange, identified by its code XNYS.

At what price were GSK (GSK) notional ADS acquired in the reported transactions?

Each acquisition was priced at $49.6700 per American Depositary Share. This single price applies to the notional ADS acquired by Dr Hal Barron, James Ford, and Maya Martinez-Davis through dividend reinvestment in their Executive Supplemental Savings Plan accounts on 15 May 2026.

What financial instrument is involved in these GSK (GSK) insider transactions?

The transactions involve GSK American Depositary Shares, referred to as ADS, with ISIN US37733W2044. The filing describes them as notional ADS held within the GSK Executive Supplemental Savings Plan accounts, rather than directly traded ordinary shares, and acquired via dividend reinvestment.